Welcome to our dedicated page for Gerresheime news (Ticker: GRRMF), a resource for investors and traders seeking the latest updates and insights on Gerresheime stock.
Gerresheimer AG (GRRMF) drives innovation in pharmaceutical packaging and drug delivery systems, serving global healthcare markets. This news hub provides investors and industry professionals with essential updates on the company's medical device developments, production expansions, and financial performance.
Access curated press releases covering earnings reports, facility openings in strategic markets, and advancements in injectable drug delivery technologies. Track updates on syringe systems, auto-injectors, and sustainable packaging solutions shaping modern healthcare infrastructure.
Our verified news collection enables informed analysis of GRRMF's position in biopharmaceutical manufacturing. Monitor regulatory milestones, partnership announcements, and capacity growth across 36 global production sites. Bookmark this page for reliable updates on one of Europe's leading providers of critical pharma solutions.
Gerresheimer AG reported a strong start to 2021, achieving revenues of EUR 303 million in Q1, a 3.1% increase year-on-year. Growth was driven by the Plastics & Devices Division, with a notable demand for syringes and pharmaceutical packaging. Adjusted EBITDA rose to EUR 54 million, reflecting a 29.3% year-on-year increase in adjusted earnings per share at EUR 0.57. The company forecasts mid single-digit revenue growth for 2021 and aims for an adjusted EBITDA margin of 22-23%. Gerresheimer is expanding production for Covid-19 vaccine vials, reinforcing its role in the pandemic response.
FAQ
What is the current stock price of Gerresheime (GRRMF)?
What is the market cap of Gerresheime (GRRMF)?
